| Cancer therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... Nature genetics 52 (11), 1219-1226, 2020 | 556 | 2020 |
| Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study NK Gillis, M Ball, Q Zhang, Z Ma, YL Zhao, SJ Yoder, ME Balasis, ... The Lancet Oncology 18 (1), 112-121, 2017 | 315 | 2017 |
| Higher genetic diversity in introduced than in native populations of the mussel Mytella charruana: evidence of population admixture at introduction sites NK Gillis, LJ Walters, FC Fernandes, EA Hoffman Diversity and Distributions 15 (5), 784-795, 2009 | 119 | 2009 |
| Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays CC Coombs, NK Gillis, X Tan, JS Berg, M Ball, ME Balasis, ... Clinical Cancer Research 24 (23), 5918-5924, 2018 | 105 | 2018 |
| Key lessons learned from Moffitt’s molecular tumor board: the clinical genomics action committee experience TC Knepper, GC Bell, JK Hicks, E Padron, JK Teer, TT Vo, NK Gillis, ... The oncologist 22 (2), 144-151, 2017 | 90 | 2017 |
| Managing clonal hematopoiesis in patients with solid tumors KL Bolton, NK Gillis, CC Coombs, K Takahashi, A Zehir, R Bejar, ... Journal of Clinical Oncology 37 (1), 7, 2019 | 79 | 2019 |
| Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next‐Generation Sequencing Era NK Gillis, JN Patel, F Innocenti Clinical Pharmacology & Therapeutics 95 (3), 269-280, 2014 | 73 | 2014 |
| Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues NK Gillis, F Innocenti Clinical Pharmacology & Therapeutics 96 (6), 655-657, 2014 | 63 | 2014 |
| Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma NY Saini, DM Swoboda, U Greenbaum, J Ma, RD Patel, K Devashish, ... Blood Cancer Discovery 3 (5), 385-393, 2022 | 60 | 2022 |
| Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort NK Gillis, JK Hicks, GC Bell, AJ Daly, PA Kanetsky, HL McLeod The Journal of investigative dermatology 137 (9), 2021, 2017 | 35 | 2017 |
| The pharmacogenomics of drug resistance to protein kinase inhibitors NK Gillis, HL McLeod Drug Resistance Updates 28, 28-42, 2016 | 33 | 2016 |
| Oncologic therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... BioRxiv, 848739, 2019 | 23 | 2019 |
| Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma LC Peres, CM Colin-Leitzinger, M Teng, J Dutil, RR Alugubelli, G DeAvila, ... Blood Advances 6 (12), 3767-3778, 2022 | 20 | 2022 |
| Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study CW McDonough, NK Gillis, A Alsultan, SW Chang, M Kawaguchi-Suzuki, ... PloS one 8 (10), e76984, 2013 | 19 | 2013 |
| Donor-derived malignancy and transplantation morbidity: risks of patient and donor genetics in allogeneic hematopoietic stem cell transplantation LS Williams, KM Williams, N Gillis, K Bolton, F Damm, NT Deuitch, ... Transplantation and cellular therapy 30 (3), 255-267, 2024 | 17 | 2024 |
| Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies EJ Gorak, M Otterstatter, T Al Baghdadi, N Gillis, JM Foran, JJ Liu, R Bejar, ... Blood advances 7 (20), 6120-6129, 2023 | 15 | 2023 |
| Cancer and aging: A call to action D Braithwaite, S Anton, S Mohile, J DeGregori, N Gillis, D Zhou, ... Aging and cancer 3 (2), 87-94, 2022 | 9 | 2022 |
| Mytella charruana along the atlantic coast of Florida: A successful invasion? M Boudreaux, N Gillis, L Walters Journal of Shellfish Research 25 (2), 713, 2006 | 9 | 2006 |
| Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study GA Abel, D Hebert, C Lee, D Rollison, N Gillis, R Komrokji, JM Foran, ... Blood Advances 7 (14), 3506-3515, 2023 | 8 | 2023 |
| Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions AE DeZern, JB Goll, RC Lindsley, R Bejar, SH Wilson, D Hebert, J Deeg, ... Blood Advances 7 (14), 3749-3759, 2023 | 8 | 2023 |
Eric PadronMalignant Hematology, H. Lee Moffitt Cancer Centerایمیل تأیید شده در moffitt.org